Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CSL Ltd CMXHF

Healthcare Biotechnology
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures... see more

Recent & Breaking News (OTCQX:CMXHF)

Danish Medicines Council Grants Approval for CSL Behring's Respreeza as Standard Treatment for Severe Alpha-1 Antitrypsin Deficiency Patients

PR Newswire January 24, 2020

CSL Behring Launches Hizentra® Co-Pay Relief Program

PR Newswire May 20, 2014

New Findings Support Less Frequent Dosing in Hemophilia B Patients Treated with Coagulation Factor IX with Recombinant Albumin (rIX-FP)

PR Newswire May 11, 2014

CSL Opens World-Class, Advanced Manufacturing Facility for Late-Stage Production of Hemophilia Therapies Now in Development

PR Newswire May 9, 2014

CSL Behring Continues Commitment to Donate Bleeding Disorder Medications to World Federation of Hemophilia

PR Newswire April 17, 2014

CSL Behring Launches My Access(TM) Cost Share Program during Hemophilia Awareness Month

PR Newswire March 25, 2014

Patient Advocates And Social Workers Will Be Trained On Intricacies Of Affordable Care Act With CSL Behring Grant

PR Newswire March 24, 2014

First patient enrolled in phase III of COMPACT, a study of volume-reduced subcutaneous C1-INH for prevention of Hereditary Angioedema (HAE) attacks

PR Newswire February 20, 2014

CSL Behring and CSL Plasma Employees Open Their Hearts to Those in Need

PR Newswire February 20, 2014

Kcentra®, from CSL Behring, Receives FDA Approval for Use in Warfarin Reversal in Patients Undergoing Surgery

PR Newswire December 13, 2013

CSL Behring Study Shows Kcentra® Superior to Plasma for Warfarin Reversal in Patients Requiring an Urgent Surgical Procedure

PR Newswire December 9, 2013

Sustainable Development And Responsible Business Practice Aren't Just Words At The CSL Group Of Companies

PR Newswire December 3, 2013

Plasma Donors Recognized For Their Lifesaving Contributions To The Treatment Of Rare Diseases

PR Newswire October 15, 2013

CSL Behring Launches MySource(TM) at the National Hemophilia Foundation's 65th Annual Meeting

PR Newswire October 3, 2013

FDA Approves New Dosing Option for CSL Behring's Hizentra®

PR Newswire September 27, 2013

CMS Approves New Technology Add-On Payment for CSL Behring's Kcentra(TM)

PR Newswire August 13, 2013

CSL Behring Presents Phase I Results From Study of Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP) in Healthy Volunteers

PR Newswire July 3, 2013

CSL Behring Presents Population Pharmacokinetic Model for Novel Recombinant Factor IX Hemophilia B Treatment That Supports Less Frequent Administration

PR Newswire July 3, 2013

CSL Behring International Trial Shows Clinical Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) for Once Weekly Prophylaxis in Patients with Severe Hemophilia B

PR Newswire July 3, 2013

CSL Behring Announces Results from Study of Recombinant Single-Chain Factor VIII (rVIII-SingleChain) for Treatment of Hemophilia A

PR Newswire July 2, 2013